VAX-31

31-valent pneumococcal conjugate vaccine · Vaxcyte, Inc.

Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for VAX-31, covering 2025-07-28 to 2026-03-31. Get the full timeline:

Most recent: Clinical Trial Update: A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age [Phase 3]

See pricing